William Blair started coverage on shares of AveXis, Inc. (NASDAQ:AVXS) in a research report released on Wednesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $107.00 price target on the stock. William Blair also issued estimates for AveXis’ Q3 2017 earnings at ($1.35) EPS, Q4 2017 earnings at ($1.39) EPS, FY2017 earnings at ($5.88) EPS, FY2018 earnings at ($6.41) EPS, FY2019 earnings at ($6.80) EPS, FY2020 earnings at ($5.00) EPS and FY2021 earnings at $7.05 EPS.

Several other analysts have also commented on the company. Evercore ISI assumed coverage on AveXis in a research note on Wednesday, August 16th. They issued an outperform rating and a $120.00 price target on the stock. Jefferies Group LLC reaffirmed a buy rating and issued a $108.00 price target (up previously from $92.00) on shares of AveXis in a research note on Friday, August 11th. Chardan Capital reaffirmed a buy rating and issued a $130.00 price target (up previously from $102.50) on shares of AveXis in a research note on Friday, August 11th. BMO Capital Markets reaffirmed a buy rating and issued a $123.00 price target on shares of AveXis in a research note on Friday, August 11th. Finally, Morgan Stanley reaffirmed an overweight rating and issued a $118.00 price target on shares of AveXis in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $102.83.

Shares of AveXis (NASDAQ AVXS) opened at 97.25 on Wednesday. The firm’s market cap is $3.10 billion. The firm’s 50-day moving average is $89.48 and its 200-day moving average is $76.66. AveXis has a 12-month low of $32.31 and a 12-month high of $99.45.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $1.10. During the same quarter last year, the business earned ($0.68) earnings per share. Equities analysts expect that AveXis will post ($5.85) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “William Blair Initiates Coverage on AveXis, Inc. (AVXS)” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://theolympiareport.com/2017/08/27/william-blair-initiates-coverage-on-avexis-inc-avxs.html.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $81.88, for a total value of $145,746.40. Following the completion of the transaction, the vice president now owns 1,780 shares in the company, valued at approximately $145,746.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 5,340 shares of company stock valued at $434,872. Corporate insiders own 18.60% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Norges Bank acquired a new position in shares of AveXis during the fourth quarter valued at about $1,193,000. Teachers Advisors LLC increased its position in shares of AveXis by 602.2% in the fourth quarter. Teachers Advisors LLC now owns 52,830 shares of the company’s stock valued at $2,522,000 after buying an additional 45,306 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new position in shares of AveXis during the first quarter valued at about $201,000. Candriam Luxembourg S.C.A. acquired a new position in shares of AveXis during the first quarter valued at about $1,901,000. Finally, Nationwide Fund Advisors increased its position in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after buying an additional 284 shares during the last quarter. Hedge funds and other institutional investors own 91.85% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.